Page 720 - Read Online

Wang et al. Hepatoma Res 2020;6:61 I http://dx.doi.org/10.20517/2394-5079.2020.55 Page 15 of 15

82. Yao F, Guo JM, Xu CF, Lou YL, Xiao BX, et al. Detecting AFP mRNA in peripheral blood of the patients with hepatocellular carcinoma,
liver cirrhosis and hepatitis. Clin Chim Acta 2005;361:119-27.
83. Zhou Y, Wang B, Wu J, Zhang C, Zhou Y, et al. Association of preoperative EpCAM circulating tumor cells and peripheral Treg cell
levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer 2016;16:506.
84. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420-32.
85. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular
carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
86. Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, et al. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating
cancer stem cells: a prospective study. Ann Surg 2011;254:569-76.
87. Li YM, Xu SC, Li J, Han KQ, Pi HF, et al. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in
hepatocellular carcinoma patients with different stages of disease. Cell Death Dis 2013;4:e831.
88. Chen J, Cao SW, Cai Z, Zheng L, Wang Q. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the
clinical stages and cancer metastasis in hepatocellular carcinoma patients. Cancer Biomark 2017;20:487-98.
89. Ou H, Huang Y, Xiang L, Chen Z, Fang Y, et al. Circulating tumor cell phenotype indicates poor survival and recurrence after surgery for
hepatocellular carcinoma. Dig Dis Sci 2018;63:2373-80.
90. Yin LC, Luo ZC, Gao YX, Li Y, Peng Q, et al. Twist expression in circulating hepatocellular carcinoma cells predicts metastasis and
prognoses. Biomed Res Int 2018;2018:3789613.
91. Ye X, Li G, Han C, Han Q, Shang L, et al. Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-
related hepatocellular carcinoma. Cancer Manag Res 2018;10:5639-47.
92. Cheng Y, Luo L, Zhang J, Zhou M, Tang Y, et al. Diagnostic value of different phenotype circulating tumor cells in hepatocellular
carcinoma. J Gastrointest Surg 2019;23:2354-61.
93. Wang Z, Luo L, Cheng Y, He G, Peng B, et al. Correlation between postoperative early recurrence of hepatocellular carcinoma and
mesenchymal circulating tumor cells in peripheral blood. J Gastrointest Surg 2018;22:633-9.
94. Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis
of patients with hepatocellular carcinoma. Cancer Res 2018;78:4731-44.
95. Chen Y, Li S, Li W, Yang R, Zhang X, et al. Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or
predictive of recurrence in hepatocellular carcinoma. Sci Rep 2019;9:7084.
96. Wang S, Zheng Y, Liu J, Huo F, Zhou J. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following
liver transplantation. J Investig Med 2018;66:1-6.
97. Xue F, Shi S, Zhang Z, Xu C, Zheng J, et al. Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing
liver transplantation. Oncol Lett 2018;15:5481-8.
98. Qi LN, Ma L, Chen YY, Chen ZS, Zhong JH, et al. Outcomes of anatomical versus non-anatomical resection for hepatocellular carcinoma
according to circulating tumour-cell status. Ann Med 2020;52:21-31.
99. Fan ZC, Yan J, Liu GD, Tan XY, Weng XF, et al. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic
model by in vivo flow cytometry assesses resection on metastasis. Cancer Res 2012;72:2683-91.
100. Ha Y, Kim TH, Shim JE, Yoon S, Jun MJ, et al. Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular
carcinoma: a prospective study. Hepatol Int 2019;13:726-35.
101. Jin J, Niu X, Zou L, Li L, Li S, et al. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood
samples is a pivotal predictive marker for metastasis. Cancer Lett 2016;378:33-7.
102. Wu X, Yang C, Yu H, Cao F, Shan Y, et al. The predictive values of serum dickkopf-1 and circulating tumor cells in evaluating the
efficacy of transcatheter arterial chemoembolization treatment on hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e16579.
103. Li Y, Huang N, Wang C, Ma H, Zhou M, et al. Impact of liver tumor percutaneous radiofrequency ablation on circulating tumor cells.
Oncol Lett 2018;16:2839-50.
104. Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, et al. Sequential circulating tumor cell counts in patients with locally advanced or
metastatic hepatocellular carcinoma: monitoring the treatment response. J Clin Med 2020;9.
105. Tayoun T, Faugeroux V, Oulhen M, Aberlenc A, Pawlikowska P, et al. CTC-derived models: a window into the seeding capacity of
circulating tumor cells (CTCs). Cells 2019;8.
106. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, et al. Identification of a population of blood circulating tumor cells
from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
107. Yan J, Fan Z, Wu X, Xu M, Jiang J, et al. Circulating tumor cells are correlated with disease progression and treatment response in an
orthotopic hepatocellular carcinoma model. Cytometry A 2015;87:1020-8.
108. Zhu L, Liu R, Zhang W, Qian S, Wang J. Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial
embolization. Clin Transl Oncol 2018;20:639-46.
109. Li J, Shi L, Zhang X, Sun B, Yang Y, et al. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in
patients with advanced hepatocellular carcinoma. Oncotarget 2016;7:2646-59.
110. Zhang Y, Zhang X, Zhang J, Sun B, Zheng L, et al. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular
carcinoma for their culture and drug sensitivity assay. Cancer Biol Ther 2016;17:1177-87.
111. Aoki M, Shoji H, Kashiro A, Takeuchi K, Shimizu Y, et al. Prospects for comprehensive analyses of circulating tumor cells in tumor
biology. Cancers (Basel) 2020;12.
112. D’Avola D, Villacorta-Martin C, Martins-Filho SN, Craig A, Labgaa I, et al. High-density single cell mRNA sequencing to characterize
circulating tumor cells in hepatocellular carcinoma. Sci Rep 2018;8:1157.